
Dermatology
Latest News
Video Series

Latest Videos
Shorts









Podcasts
CME Content
More News

Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.

In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.

A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.

US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.

Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.

Phase 3 extension shows oral denifanstat sustains acne lesion reductions through 52 weeks, with 57% IGA success and 77% fewer inflammatory lesions.

Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.

New ARCADIA and OLYMPIA LTE data show nemolizumab sustained skin clearance and itch relief for up to 3 years in atopic dermatitis and prurigo nodularis.

In this session, Cheri Frey, MD, shared a framework for evaluating skincare products, from ingredient plausibility to clinically meaningful results.

Andrea Murina, MD, reviewed strategies for optimizing HS biologics, combining therapies, and reconsidering the role of surgery.

HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.

Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.

In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.










































































